Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 79Nasopharyngeal Carcinoma 51Uterine Cervical Neoplasms 44Lung Neoplasms 38Esophageal Neoplasms 32Head and Neck Neoplasms 28Esophageal Squamous Cell Carcinoma 28Squamous Cell Carcinoma of Head and Neck 22Stomach Neoplasms 20Breast Neoplasms 16Small Cell Lung Carcinoma 15Recurrence 12Neoplasm Metastasis 12Nasopharyngeal Neoplasms 12Carcinoma, Squamous Cell 10Ovarian Neoplasms 9Central Nervous System Neoplasms 9Neuroblastoma 8Lymphoma, Large B-Cell, Diffuse 8Pancreatic Neoplasms 7Lymphoma 7Hypopharyngeal Neoplasms 7Triple Negative Breast Neoplasms 6Oropharyngeal Neoplasms 6Neoplasms 6Biliary Tract Neoplasms 6Urinary Bladder Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Follicular 5

Interventions

pembrolizumab 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Nonsquamous Non-small Cell Lung Cancer × Cisplatin × Clear all
NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡